News & Events – Sumitovant

Select Company

July 27, 2022Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
June 17, 2022Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 2 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women with Endometriosis-Associated Pain
June 02, 2022Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
May 10, 2022Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
May 09, 2022Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
April 29, 2022Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
February 25, 2022Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
February 07, 2022Myovant Sciences to Present at Upcoming Investor Conferences
January 26, 2022Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
October 12, 2021Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
1 2 3 … 9 Next »